Search | Clinical Trials Finder

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions: Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hot Flashes, Menopause, Vasomotor Symptoms
Interventions: Escitalopram, Placebo; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Oakland, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more

Conditions: Sexual Dysfunction
Interventions: Ropinirole (Requip); Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: No Intervention; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Homewood, Alabama • California City, California + 15 more

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Redlands, California • Sherman Oaks, California • Wildomar, California + 24 more

Conditions: Major Depressive Disorder
Interventions: Creatine, Placebo; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Down Syndrome, Depression
Interventions: Fluoxetine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Treatment Resistant Depression
Interventions: Intranasal esketamine; Drug
Lead sponsor: Psych Atlanta; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Pulmonary Disease, Chronic Obstructive, Major Depression
Interventions: Treatment Adherence Intervention, Enhanced Care; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 95 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 3
States / cities: West Haverstraw, New York • White Plains, New York

Conditions: Depressive Disorder, Major
Interventions: Standard of Care (SOC); Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: LY2216684, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 21 more

Conditions: Depression, Major Depressive Disorder
Interventions: AXS-05, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 43
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 39 more

Conditions: Major Depressive Disorder
Interventions: paroxetine CR; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 71
States / cities: Birmingham, Alabama • Fairfield, Alabama • Mobile, Alabama + 63 more

Conditions: Tracheostomy Complication
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Depression
Interventions: SSRI + LD, SSRI + PHD; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sexual Dysfunction
Interventions: Viveve System; Device
Lead sponsor: Michael Krychman, MD; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: General Anxiety Disorder, Social Anxiety Disorder
Interventions: Namenda/Memantine; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Acute Stroke, Visual Field Loss
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Bogachan Sahin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Solid Tumors
Interventions: Vadimezan™; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 4
States / cities: Indianapolis, Indiana • Minneapolis, Minnesota • St Louis, Missouri + 1 more

Conditions: Psychotic Depression
Interventions: Aripiprazole; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Knee Osteoarthritis, Depression
Interventions: Aerobic exercise, Duloxetine; Behavioral · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions: Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Major Depressive Disorder
Interventions: EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo; Drug
Lead sponsor: Euthymics BioScience, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 43
States / cities: Arcadia, California • Beverly Hills, California • National City, California + 39 more

Conditions: Irritable Bowel Syndrome
Interventions: Citalopram, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

A Study in Prevention of Re-emergence of Depression Symptoms

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Fluoxetine Treatment of Depression in Down Syndrome

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

A Trial of AXS-05 in Patients With Major Depressive Disorder

Major Depressive Disorder Study In Adults

Safety of Percutaneous Tracheostomy in Clopidogrel and Selective Serotonin Reuptake Inhibitors

Adding Exercise to Antidepressant Medication Treatment for Depression

A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

Fluoxetine for Visual Recovery After Ischemic Stroke

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

Exercise Plus Duloxetine for Knee Osteoarthritis

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Citalopram in Irritable Bowel Syndrome